Podophyllotoxin Derivatives: LAT1-Targeted Compounds for Esophageal Cancer

A 2026 dataset from figshare by Manwei Jia describes novel podophyllotoxin derivatives designed to target LAT1 transporters. The data includes experimental results for compound B11, showing a 64.6% tumor growth inhibition in Eca109 xenograft models and a more than 4-fold improvement in animal tolerability compared to etoposide. The dataset is 1.2 MB in size and is shared under a CC-BY-NC-4.0 license.

Use Cases

• Modeling structure-activity relationships based on novel podophyllotoxin derivative designs.
• Analyzing tumor selectivity and drug distribution based on LAT1-targeting mechanisms described.
• Comparing in vivo efficacy and tolerability metrics based on reported tumor growth inhibition (TGI) and maximum tolerated dose (MTD) data.
• Investigating cytoskeleton disruption as an antitumor mechanism based on the described mechanistic studies.

Strengths

• Includes specific quantitative results, such as a 64.6% TGI for compound B11 versus 30.6% for etoposide.
• Reports a concrete safety improvement, with B11 showing a more than 4-fold increase in animal tolerability.
• Data is associated with a specific, recent update date of 2026-04-14.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• The dataset is small (1.2 MB), suggesting limited scope or a focused subset of experimental data.

Provenance

Source

figshare, author Manwei Jia.

Collection Method

Likely contains synthesized experimental data from drug design, synthesis, and in vitro/in vivo testing.

Time Range

Experimental data is contemporary, with a 2026 publication date.

Freshness

Last updated 2026-04-14 08:16:48.

Geography

null